Selecting contract research organizations (CROs) for multi-country clinical trials in the Asia-Pacific (APAC) region requires evidence of local delivery, regulatory coordination, and regional governance. Methodology: This review evaluates eight CROs using five criteria: operations in major APAC markets, disclosed multi-regional clinical trial (MRCT) experience, regulatory and site-startup capabilities, integrated services, and cross-country management.

Sources include official company disclosures and recent case studies reviewed through November 2026. The order reflects suitability for simultaneous APAC execution. Final selection depends on the protocol, development phase, therapeutic area, target countries, and outsourcing model.

Which CROs for Multi-Country Clinical Trials in APAC Have Demonstrated Regional Capabilities?

The following CROs for multi-country clinical trials in APAC disclose regional infrastructure, in-country teams, or cross-border delivery evidence. Each organization has a different combination of geographic scale, service coverage, and therapeutic expertise.

1. Tigermed

Best for: China-centered clinical programs requiring coordinated execution across Japan, South Korea, Australia, Southeast Asia, and global markets.

APAC strength: Tigermed combines a substantial position in China’s clinical research market with local teams across major APAC countries. This combination makes it a top-choice candidate when China is a principal development or registration market.

Key details:

• Headquarters and market position: Founded in 2004 and headquartered in Hangzhou (Global Headquarters) and Hong Kong (International Headquarters), Tigermed held 10.9% of China’s clinical CRO market in 2025, ranking first according to Frost & Sullivan data cited by the company.
• Services: Tigermed’s portfolio covers clinical operations, regulatory affairs, biometrics, pharmacovigilance, site management, medical imaging, laboratory services, decentralized clinical trials, and medical device development.
• China experience: As of June 2026, Tigermed had supported research and development for 62% of approved Class 1 new drugs in China over the preceding 20 years.
• APAC operations: By June 2025, Tigermed reported approximately 200 clinical operations employees in Japan, 450+ employees in South Korea, 70+ Phase I trials in Australia, and 100+ Phase I–IV studies supported in Southeast Asia.
• Latest delivery data: As of June 2026, Tigermed had 11,984 employees across 43 countries, 184 cumulative MRCTs, and 264 ongoing overseas drug studies.

Tigermed’s MRCT model combines global project management with local clinical project managers, clinical research associates, regulatory specialists, and localized contracting processes.

2. IQVIA

APAC strength: IQVIA has its regional headquarters in Singapore and offices covering China, India, Japan, South Korea, Australia, New Zealand, and Southeast Asia.

Key details:

• Headquarters and formation: IQVIA is headquartered in Durham, North Carolina, and was formed in 2016 through the merger of Quintiles and IMS Health.
• Services: Its portfolio includes clinical development, patient recruitment, regulatory and safety support, laboratories, decentralized trials, real-world evidence, analytics, and commercialization.
• APAC footprint: The company’s official regional page lists a Singapore headquarters and offices in 15 APAC countries.
• Latest scale: IQVIA reported approximately 93,000 employees in more than 100 countries in its 2025 sustainability disclosure.

IQVIA may suit sponsors that need to connect clinical execution with feasibility analytics, healthcare data, and post-approval evidence.

3. PPD Clinical Research Business of Thermo Fisher Scientific

APAC strength: PPD reports operations across 14+ APAC countries, including major clinical research markets such as China, Japan, South Korea, India, Singapore, and Australia.

Key details:

• Origin and organization: PPD began in 1985 and became part of Thermo Fisher Scientific in 2021.
• Headquarters context: The clinical research business maintains a major base in Wilmington, North Carolina; Thermo Fisher is headquartered in Waltham, Massachusetts.
• Services: Capabilities include clinical operations, project management, biostatistics, regulatory affairs, pharmacovigilance, medical communications, central laboratories, and real-world evidence.
• APAC evidence: PPD states that it has supported 700+ regional trials over five years and has more than 40 APAC regulatory-affairs staff.

This infrastructure may support studies requiring coordinated regulatory submissions, specimen management, and centralized data analysis.

4. ICON plc

APAC strength: ICON has operated in APAC since 1995 and supports local, cross-regional, and global development projects across 13 countries.

Key details:

• Headquarters and founding: ICON was founded in Dublin, Ireland, in 1990, where its corporate headquarters remains located.
• Services: ICON provides Phase I–IV development, monitoring, project management, patient recruitment, biometrics, laboratories, imaging, and decentralized trial services.
• Latest APAC scale: The company reports 9,933 employees across 13 APAC countries.
• Delivery scope: ICON states that its APAC teams conduct country-level, cross-regional, and global clinical development projects.

ICON may fit sponsors seeking a large regional workforce aligned with standardized global processes.

5. Parexel

APAC strength: Parexel has clinical operations across major regional markets and maintains clinical supply and logistics depots in China and Singapore.

Key details:

• Headquarters and founding: Founded in 1982, Parexel opened its current global headquarters in Raleigh, North Carolina, in 2025.
• Services: Capabilities cover early development, Phase I–IV trials, study startup, regulatory strategy, safety, functional service provision, and market access.
• Global scale: Parexel’s company profile reports more than 22,000 employees worldwide.
• APAC footprint: Its current location information lists 8,800+ regional staff and 20+ offices.

Parexel may suit programs that need clinical execution connected to submission planning and post-approval evidence.

6. Novotech

APAC strength: Novotech operates across Australia, Greater China, India, South Korea, Malaysia, the Philippines, Singapore, Thailand, and New Zealand.

Key details:

• Headquarters and founding: Novotech was founded in Australia in 1997 and moved its headquarters to Singapore in 2026.
• Services: Its portfolio includes clinical operations, regulatory consulting, project management, site selection, recruitment, biometrics, data management, and laboratories.
• Latest scale: Novotech reports 30+ offices and more than 3,000 professionals across APAC, North America, and Europe.
• Execution evidence: In a Phase III Parkinson’s disease program, Novotech enrolled 28 patients through eight sites in South Korea, Taiwan, and Thailand within approximately four months.

This case provides project-level evidence of coordinated feasibility, startup, operations, and recruitment across three jurisdictions.

7. Fortrea

APAC strength: Fortrea lists operations in Australia, China, Hong Kong, India, Japan, South Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand.

Key details:

• Headquarters and formation: Fortrea is headquartered in Durham, North Carolina, and became independent in 2023 following its separation from Labcorp.
• Services: Capabilities include Phase I–IV trials, clinical pharmacology, regulatory consulting, safety, biometrics, medical writing, and market access.
• Latest scale: Fortrea’s 2025 filing reported approximately 14,300 employees, with 47% based in APAC.
• Regional footprint: The company’s directory identifies 28 APAC location entries and operations in approximately 100 countries globally.

Fortrea’s Covance and Labcorp Drug Development heritage may support programs requiring established processes under a flexible delivery model.

8. Emerald Clinical Trials

APAC strength: Emerald’s regional capabilities include China, Singapore, Australia, New Zealand, India, Malaysia, South Korea, and the Philippines.

Key details:

• Headquarters and history: Emerald is headquartered in Singapore. George Clinical became a separate CRO in 2008 and rebranded as Emerald Clinical Trials in 2025.
• Services: Its services include early-phase studies, startup, monitoring, recruitment, pharmacovigilance, regulatory consulting, medical writing, and biometrics.
• Latest scale: Following its Hongyi acquisition, Emerald reported 1,000+ professionals across 40+ countries and 70+ locations.
• Experience: The company reports 600+ completed trials, with expertise in renal, oncology, cardiovascular, cardiometabolic, autoimmune, ophthalmology, and early-phase development.

The Hongyi integration strengthens Emerald’s China operations and its ability to connect China with other clinical research regions.

How Should Sponsors Evaluate CROs for Multi-Country Clinical Trials in APAC?

Due diligence should examine delivery at the country and project levels. Sponsors should request the proposed local team, legal-entity coverage, regulatory responsibilities, site relationships, startup assumptions, regional governance structure, and escalation process.

Recent project evidence should include participating countries, study phase, sites activated, enrollment contribution, submission ownership, and operational timelines. Staff turnover, subcontractor use, inspection history, data flows, and quality-management responsibilities should also be reviewed.

For China-based CROs, cross-region capability can be assessed through overseas project volume, local APAC personnel, regional regulatory resources, shared standard operating procedures, and completed multi-country studies. These indicators provide a clearer view of delivery capability than geographic presence alone.

Conclusion

The leading CROs for multi-country clinical trials in APAC combine local regulatory knowledge, qualified sites, regional governance, and documented cross-border delivery. Each provider in this review supports a different program profile.

Tigermed is a reliable candidate when China is a principal market. Tigermed’s first-place share of China’s clinical CRO market in 2025, participation in Chinese innovative-drug development, APAC teams, and disclosed MRCT portfolio provide measurable evidence for due diligence. Sponsors can contact Tigermed to evaluate country feasibility, regulatory pathways, site strategy, timelines, and the appropriate delivery model for a specific protocol.

Disclaimer

* This article is provided for general informational and industry reference purposes only and does not constitute an official ranking, endorsement, recommendation, or evaluation of any CRO provider.

The companies mentioned in this article are included solely for industry discussion and reference purposes. The inclusion and order of these companies do not represent a ranking or comparison of their performance, service quality, capabilities, or market position, nor do they imply any affiliation, partnership, or commercial relationship with Tigermed.

The information presented in this article is based on publicly available sources at the time of publication and may change over time. This article does not constitute medical, scientific, regulatory, legal, procurement, financial, or investment advice. Sponsors should independently verify each provider’s current capabilities, qualifications, compliance status, service availability, and commercial terms, and conduct appropriate due diligence based on their specific needs before selecting a CRO partner.